Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01137474 · ClinicalTrials.gov registry record · Phase 3
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,996
- Enrollment target
NCT01137474: Completed Phase 3 study, sponsored by AstraZeneca.
NCT01137474 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 2,996 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (288% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01137474, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,996 participants
- Enrollment target
Study Summary
The purpose of this study is to learn whether dapagliflozin, after 12 weeks, can improve (decrease) blood pressure in patients with type 2 diabetes with uncontrolled hypertension who are on an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker. The safety of this treatment will also be studied.
Primary Outcome
Seated BP was to be measured at every visit. Data after rescue medication was excluded. The patient first rested for at least 10 minutes in the seated position. Seated blood BP was determined from the mean of 3 replicated measurements obtained at least 1 minute apart. However, if the 3 consecutive seated BP readings were not within 8 mm Hg of each other, an additional 2 BP readings were to be obtained (total=5) and incorporated into the calculated mean for systolic BP and diastolic BP. For the i
Interventions
- DRUG Dapagliflozin
- DRUG Placebo-matching dapagliflozin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,996 participants |
| Start Date | 2010-07 |
| Est. Completion | 2013-02 |
| Phase | Phase 3 |
What the finished NCT01137474 record still lists
NCT01137474 is an interventional study that assigns participants to a tested intervention. Its 2,996 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (288% higher).
The record links to 0 conditions, and to 2 interventions - of which Dapagliflozin is the first listed.
NCT01137474 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01137474 about?
NCT01137474 is a clinical study titled "A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker". The purpose of this study is to learn whether dapagliflozin, after 12 weeks, can improve (decrease) blood pressure in patients with type 2 diabetes with uncontrolled hypertension who are on an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker. The safety of this treatment wi...
What is the current status of trial NCT01137474?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,996 participants. The study started on 2010-07. Estimated completion is 2013-02.
What interventions are being tested in trial NCT01137474?
The interventions under investigation include: Dapagliflozin (DRUG), Placebo-matching dapagliflozin (DRUG).
Who is sponsoring clinical trial NCT01137474?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01137474's enrollment target sits among peer trials
2,996 80th of 2000 higher than 1,921 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05297734 · 2,996 participants · NA
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
- NCT03860883 · 2,998 participants · NA
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
- NCT00004847 · 3,000 participants · Phase 1
Diagnosis of Pheochromocytoma
- NCT00478712 · 3,000 participants
Hirschsprung Disease Genetic Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia